[Therapy of Metastatic Non-small Cell Lung Cancer].
Lung cancer accounts for the leading cause of cancer deaths in Germany and is characterized by early metastasis formation. The majority of patients with non-small cell lung cancer (NSCLC) will receive systemic therapy for treatment of their disease. Importantly together with the identification of targetable oncogenic alterations, systemic treatment of NSCLC has dramatically changed in recent years with the implementation of various new agents such as tyrosine kinase inhibitors, anti angiogenic agents, and immune modulating drugs. However, these new therapeutic options also challenge the treating physician since molecular, histologic, and clinical factors need to be considered for the clinical decision-making. Moreover, supportive therapy including bronchoscopic therapy has evolved. The following therapy recommendations will summarize the up-to date treatment strategies for metastatic NSCLC.
Asklepios Fachkliniken München-Gauting, Thorakale Onkologie, Gauting.
N
N
Reinmuth
Ambulantes Aachener Zentrum für Lungen- und Bronchialheilkunde, Aachen.
A
A
Gröschel
Klinikverbund Kempten-Oberallgäu, Klinik für Pneumologie, Thoraxonkologie, Schlaf- und Beatmungsmedizin, Kempten.
C
C
Schumann
Universitätsklinik Frankfurt, Klinik für Innere Medizin, Hämatologie und Onkologie, Frankfurt.
M
M
Sebastian
Universitätsklinikum Münster, Medizinische Klinik und Poliklinik A.
R
R
Wiewrodt
LungenClinic Grosshansdorf, Onkologischer Schwerpunkt, Airway Research Center North (ARCN), Deutsches Zentrum für Lungenforschung (DZL), Großhansdorf.
M
M
Reck
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001999:Bronchoscopy / Q000379:methods*; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis / Q000556:secondary* / Q000628:therapy*; D003131:Combined Modality Therapy / Q000379:methods; D019317:Evidence-Based Medicine; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D008175:Lung Neoplasms / Q000175:diagnosis / Q000628:therapy*; D058990:Molecular Targeted Therapy / Q000379:methods*; D018579:Patient Selection; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D047428:Protein Kinase Inhibitors